Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of FCR versus BR in previously untreated chronic lymphocytic leukemia
2007-007587-21Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab, fludarabine, cyclophosphamide and bendamustine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by University of Cologne. Primary endpoint: progression-free survival. Started Apr 2008; status: completed.
02
Drugs
rituximabfludarabinecyclophosphamidebendamustine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2007-007587-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007587-21.